文献速递帕金森病与运动障碍

普拉克索缓释片? 不,普瑞登坦单药治疗早期帕金森病的随机试验

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
PubMed 文献 · Neurology · 2017-05-10

这项随机、双盲、安慰剂和活性对照的3期试验纳入病程<5年、尚未使用左旋多巴或多巴胺激动剂的早期帕金森病患者1007例,评估腺苷2a受体拮抗剂普瑞登坦单药治疗。26周时普瑞登坦2、5、10 mg每日两次及雷沙吉兰1 mg均未优于安慰剂;活性对照雷沙吉兰缺乏疗效使结果难以解读。

要点

  • 普瑞登坦单药在26周时未优于安慰剂。
  • 活性对照雷沙吉兰亦未优于安慰剂,试验解读受限。
  • 普瑞登坦总体耐受性良好,因不良事件停药比例低。

核心结论

  • 该3期试验未观察到支持普瑞登坦单药治疗早期帕金森病有效的证据。
  • 活性对照雷沙吉兰缺乏疗效,使结果难以解读。

研究设计与样本

  • 随机、26周、安慰剂和活性对照、平行组、多中心、双盲试验。
  • 纳入病程<5年、尚未接受左旋多巴或多巴胺激动剂的帕金森病成人患者。
  • UPDRS第3部分评分≥10且Hoehn & Yahr评分≤3。
  • 按1:1:1:1:1随机分配至普瑞登坦2、5、10 mg每日两次、雷沙吉兰1 mg每日一次或安慰剂。
  • 共治疗1007例患者。

主要发现

  • 26周时普瑞登坦和雷沙吉兰均未优于安慰剂。
  • UPDRS2+3评分与安慰剂的差异(负值表示优于安慰剂):普瑞登坦2 mg=2.60(0.86, 4.30)。
  • 普瑞登坦5 mg=1.30(-0.41, 2.94),10 mg=0.40(-1.29, 2.11)。
  • 雷沙吉兰1 mg=0.30(-1.35, 2.03)。
  • 事后分析未发现可解释试验失败的单一致病因素。

关键数值与推荐

  • 主要终点为第26周UPDRS第2部分(日常生活活动)与第3部分评分之和较基线的变化。
  • 疗效证据等级:Class I证据表明普瑞登坦在2、5、10 mg剂量下单药治疗早期帕金森病无效。

临床怎么用

  • 不推荐普瑞登坦2、5、10 mg单药用于早期帕金森病治疗。
  • 活性对照失败提示需谨慎解读该阴性试验的结果。

局限性

  • 活性对照雷沙吉兰未显示优于安慰剂,限制了试验结果的解释。
  • 事后分析未找到试验失败的单一致病因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic drug for the treatment of Parkinson disease (PD) when given as monotherapy. METHODS: This was a randomized, 26-week, placebo- and active-controlled, parallel-group, multicenter, double-blind trial conducted in adults diagnosed with PD for <5 years who were not yet receiving l-dopa or dopamine agonists. Patients with a Unified Parkinson's Disease Rating Scale (UPDRS) part 3 (motor function) score ≥10 and Hoehn & Yahr score ≤3 were randomized 1:1:1:1:1 to preladenant 2, 5, or 10 mg twice daily, rasagiline 1 mg (active-control) once daily, or placebo. The primary endpoint was the change from baseline at week 26 in the sum of UPDRS parts 2 (activities of daily living) and 3 scores (UPDRS2+3). RESULTS: The number of patients treated was 1,007. Neither preladenant nor rasagiline was superior to placebo after 26 weeks. The differences vs placebo (95% confidence interval) in UPDRS2+3 scores (with a negative difference indicating improvement vs placebo) were preladenant 2 mg = 2.60 (0.86, 4.30), preladenant 5 mg = 1.30 (-0.41, 2.94), preladenant 10 mg = 0.40 (-1.29, 2.11), and rasagiline 1 mg = 0.30 (-1.35, 2.03). Post hoc analyses did not identify a single causal factor that could explain the finding of a failed trial. Preladenant was generally well-tolerated with few patients discontinuing due to adverse events (preladenant 7%, rasagiline 3%, placebo 4%). CONCLUSIONS: No evidence supporting the efficacy of preladenant as monotherapy was observed in this phase 3 trial. The lack of efficacy of the active control rasagiline makes it difficult to interpret the results. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov: NCT01155479. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with early PD, preladenant is not effective as monotherapy at the doses studied (2, 5, 10 mg).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Stocchi F, Rascol O, Hauser RA, et al. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017. PMID: 28490648. doi:10.1212/WNL.0000000000004003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。